Literature DB >> 20522089

Profile of cognitive impairment in Parkinson's disease.

G Stennis Watson1, James B Leverenz.   

Abstract

Cognitive impairment (CI) is a common nonmotor complication of Parkinson's disease (PD), and is associated with significant disability for patients and burden for caregivers. Similar to motor symptoms, the characteristics of CI in PD can be quite variable, both in terms of what cognitive domains are impaired, and the timing of onset and rate of progression. This review will examine the profile of cognitive domain impairments observed in PD, with a focus on early CI (without dementia). We will also discuss possible relationships between specific cognitive domain impairments in PD and pathological processes such as Lewy-related pathology and Alzheimer's disease. It is our hypothesis that the specific characteristics of CI observed in individual PD patients provide clues to the underlying pathological processes, and that understanding the biological basis of this clinical phenomenon will assist in directing disease-specific treatments. Given the high lifetime risk for CI in PD, it is imperative that we improve our understanding and treatments for this common and disabling problem in PD.

Entities:  

Mesh:

Year:  2010        PMID: 20522089      PMCID: PMC3049172          DOI: 10.1111/j.1750-3639.2010.00373.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  55 in total

1.  Impaired visual search in drivers with Parkinson's disease.

Authors:  Ergun Y Uc; Matthew Rizzo; Steven W Anderson; JonDavid Sparks; Robert L Rodnitzky; Jeffrey D Dawson
Journal:  Ann Neurol       Date:  2006-10       Impact factor: 10.422

2.  Subtypes of mild cognitive impairment in Parkinson's disease: progression to dementia.

Authors:  Carmen Cristea Janvin; Jan Petter Larsen; Dag Aarsland; Kenneth Hugdahl
Journal:  Mov Disord       Date:  2006-09       Impact factor: 10.338

3.  Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort.

Authors:  E Y Uc; M P McDermott; K S Marder; S W Anderson; I Litvan; P G Como; P Auinger; K L Chou; J C Growdon
Journal:  Neurology       Date:  2009-11-03       Impact factor: 9.910

4.  Cognitive profiles of individual patients with Parkinson's disease and dementia: comparison with dementia with lewy bodies and Alzheimer's disease.

Authors:  Carmen Cristea Janvin; Jan Petter Larsen; David P Salmon; Douglas Galasko; Kenneth Hugdahl; Dag Aarsland
Journal:  Mov Disord       Date:  2006-03       Impact factor: 10.338

5.  Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia.

Authors:  N I Bohnen; D I Kaufer; R Hendrickson; L S Ivanco; B J Lopresti; G M Constantine; Ch A Mathis; J G Davis; R Y Moore; S T Dekosky
Journal:  J Neurol       Date:  2005-09-02       Impact factor: 4.849

6.  Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

Authors:  Yaroslau Compta; María J Martí; Naroa Ibarretxe-Bilbao; Carme Junqué; Francesc Valldeoriola; Esteban Muñoz; Mario Ezquerra; Jose Ríos; Eduardo Tolosa
Journal:  Mov Disord       Date:  2009-11-15       Impact factor: 10.338

7.  Neuroanatomical substrate of visuospatial and visuoperceptual impairment in Parkinson's disease.

Authors:  Joana B Pereira; Carme Junqué; María-Jośe Martí; Blanca Ramirez-Ruiz; Nuria Bargalló; Eduardo Tolosa
Journal:  Mov Disord       Date:  2009-06-15       Impact factor: 10.338

Review 8.  Biological fluid biomarkers in neurodegenerative parkinsonism.

Authors:  Michael Eller; David R Williams
Journal:  Nat Rev Neurol       Date:  2009-09-01       Impact factor: 42.937

Review 9.  Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium.

Authors:  I G McKeith; D W Dickson; J Lowe; M Emre; J T O'Brien; H Feldman; J Cummings; J E Duda; C Lippa; E K Perry; D Aarsland; H Arai; C G Ballard; B Boeve; D J Burn; D Costa; T Del Ser; B Dubois; D Galasko; S Gauthier; C G Goetz; E Gomez-Tortosa; G Halliday; L A Hansen; J Hardy; T Iwatsubo; R N Kalaria; D Kaufer; R A Kenny; A Korczyn; K Kosaka; V M Y Lee; A Lees; I Litvan; E Londos; O L Lopez; S Minoshima; Y Mizuno; J A Molina; E B Mukaetova-Ladinska; F Pasquier; R H Perry; J B Schulz; J Q Trojanowski; M Yamada
Journal:  Neurology       Date:  2005-10-19       Impact factor: 9.910

Review 10.  Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options.

Authors:  Caroline H Williams-Gray; Thomas Foltynie; Simon J G Lewis; Roger A Barker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

View more
  35 in total

1.  Neuropsychologic assessment in collaborative Parkinson's disease research: a proposal from the National Institute of Neurological Disorders and Stroke Morris K. Udall Centers of Excellence for Parkinson's Disease Research at the University of Pennsylvania and the University of Washington.

Authors:  G Stennis Watson; Brenna A Cholerton; Rachel G Gross; Daniel Weintraub; Cyrus P Zabetian; John Q Trojanowski; Thomas J Montine; Andrew Siderowf; James B Leverenz
Journal:  Alzheimers Dement       Date:  2012-11-16       Impact factor: 21.566

2.  Cerebral perfusion and cortical thickness indicate cortical involvement in mild Parkinson's disease.

Authors:  Tara M Madhyastha; Mary K Askren; Peter Boord; Jing Zhang; James B Leverenz; Thomas J Grabowski
Journal:  Mov Disord       Date:  2015-03-11       Impact factor: 10.338

Review 3.  Role of the endolysosomal system in Parkinson's disease.

Authors:  D J Vidyadhara; John E Lee; Sreeganga S Chandra
Journal:  J Neurochem       Date:  2019-07-31       Impact factor: 5.372

4.  Relation between Olfactory Dysfunction and Episodic Verbal Memory in Early Parkinson's Disease.

Authors:  Lütfü Hanoğlu; Hüsniye Aylin Hakyemez; Feriha Özer; Serkan Özben; Sema Demirci; Emel Oğuz Akarsu
Journal:  Noro Psikiyatr Ars       Date:  2014-12-01       Impact factor: 1.339

5.  The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers.

Authors:  Jasmohan S Bajaj; James B Wade; Douglas P Gibson; Douglas M Heuman; Leroy R Thacker; Richard K Sterling; R Todd Stravitz; Velimir Luketic; Michael Fuchs; Melanie B White; Debulon E Bell; HoChong Gilles; Katherine Morton; Nicole Noble; Puneet Puri; Arun J Sanyal
Journal:  Am J Gastroenterol       Date:  2011-05-10       Impact factor: 10.864

6.  Neuropsychological Subgroups in Non-Demented Parkinson's Disease: A Latent Class Analysis.

Authors:  Laura Brennan; Kathryn M Devlin; Sharon X Xie; Dawn Mechanic-Hamilton; Baochan Tran; Howard H Hurtig; Alice Chen-Plotkin; Lama M Chahine; James F Morley; John E Duda; David R Roalf; Nabila Dahodwala; Jacqueline Rick; John Q Trojanowski; Paul J Moberg; Daniel Weintraub
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

Review 7.  Caffeine as an attention enhancer: reviewing existing assumptions.

Authors:  Suzanne J L Einöther; Timo Giesbrecht
Journal:  Psychopharmacology (Berl)       Date:  2012-12-16       Impact factor: 4.530

8.  APOE, MAPT, and SNCA genes and cognitive performance in Parkinson disease.

Authors:  Ignacio F Mata; James B Leverenz; Daniel Weintraub; John Q Trojanowski; Howard I Hurtig; Vivianna M Van Deerlin; Beate Ritz; Rebecca Rausch; Shannon L Rhodes; Stewart A Factor; Cathy Wood-Siverio; Joseph F Quinn; Kathryn A Chung; Amie L Peterson; Alberto J Espay; Fredy J Revilla; Johnna Devoto; Shu-Ching Hu; Brenna A Cholerton; Jia Y Wan; Thomas J Montine; Karen L Edwards; Cyrus P Zabetian
Journal:  JAMA Neurol       Date:  2014-11       Impact factor: 18.302

9.  Pharmacological and chemogenetic orexin/hypocretin intervention ameliorates Hipp-dependent memory impairment in the A53T mice model of Parkinson's disease.

Authors:  Milos Stanojlovic; Jean Pierre Pallais; Michael K Lee; Catherine M Kotz
Journal:  Mol Brain       Date:  2019-10-30       Impact factor: 4.041

Review 10.  Dementia with Lewy bodies - from scientific knowledge to clinical insights.

Authors:  Nikitas A Arnaoutoglou; John T O'Brien; Benjamin R Underwood
Journal:  Nat Rev Neurol       Date:  2019-02       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.